Law360, New York ( June 23, 2015, 10:14 AM EDT) -- On May 7, 2015, the Supreme Court of California issued an opinion in In re Cipro Cases I & II, a case centered on pay-for-delay settlements between drug makers and generic manufacturers. The court found the existence of an issue of fact as to whether a settlement in which the branded manufacturer paid generic manufacturers to stay out of the market until the expiration of the patent on the branded drug violated California state antitrust law. At issue in the case was a 1997 settlement agreement between Bayer AG and Barr Laboratories Inc., pursuant to which Bayer paid Barr approximately $400 million to delay marketing a generic version of Cipro — a drug produced by Bayer — until Bayer's patent on Cipro expired in late 2003....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
